HeXun Biosciences Statistics

Total Valuation

HeXun Biosciences has a market cap or net worth of TWD 3.52 billion. The enterprise value is 3.27 billion.

Market Cap	3.52B
Enterprise Value	3.27B

Important Dates

The next estimated earnings date is Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

HeXun Biosciences has 46.00 million shares outstanding. The number of shares has increased by 10.22% in one year.

Current Share Class	n/a
Shares Outstanding	46.00M
Shares Change (YoY)	+10.22%
Shares Change (QoQ)	-0.16%
Owned by Insiders (%)	0.31%
Owned by Institutions (%)	n/a
Float	45.86M

Valuation Ratios

The trailing PE ratio is 28.36.

PE Ratio	28.36
Forward PE	n/a
PS Ratio	14.90
PB Ratio	6.39
P/TBV Ratio	6.76
P/FCF Ratio	116.28
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 23.87, with an EV/FCF ratio of 108.21.

EV / Earnings	26.37
EV / Sales	13.85
EV / EBITDA	23.87
EV / EBIT	28.17
EV / FCF	108.21

Financial Position

The company has a current ratio of 12.69, with a Debt / Equity ratio of 0.06.

Current Ratio	12.69
Quick Ratio	12.11
Debt / Equity	0.06
Debt / EBITDA	0.25
Debt / FCF	1.12
Interest Coverage	74.05

Financial Efficiency

Return on equity (ROE) is 25.43% and return on invested capital (ROIC) is 13.38%.

Return on Equity (ROE)	25.43%
Return on Assets (ROA)	12.81%
Return on Capital (ROIC)	13.38%
Revenue Per Employee	6.75M
Profits Per Employee	3.55M
Employee Count	35
Asset Turnover	0.42
Inventory Turnover	2.64

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +17.58% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+17.58%
50-Day Moving Average	73.21
200-Day Moving Average	69.34
Relative Strength Index (RSI)	58.42
Average Volume (20 Days)	106,581

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HeXun Biosciences had revenue of TWD 236.41 million and earned 124.21 million in profits. Earnings per share was 2.70.

Revenue	236.41M
Gross Profit	216.71M
Operating Income	116.26M
Pretax Income	124.21M
Net Income	124.21M
EBITDA	133.82M
EBIT	116.26M
Earnings Per Share (EPS)	2.70

Full Income Statement

Balance Sheet

The company has 277.84 million in cash and 33.76 million in debt, giving a net cash position of 244.08 million or 5.31 per share.

Cash & Cash Equivalents	277.84M
Total Debt	33.76M
Net Cash	244.08M
Net Cash Per Share	5.31
Equity (Book Value)	550.63M
Book Value Per Share	11.97
Working Capital	360.65M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 66.73 million and capital expenditures -36.46 million, giving a free cash flow of 30.26 million.

Operating Cash Flow	66.73M
Capital Expenditures	-36.46M
Free Cash Flow	30.26M
FCF Per Share	0.66

Full Cash Flow Statement

Margins

Gross margin is 91.67%, with operating and profit margins of 49.18% and 52.54%.

Gross Margin	91.67%
Operating Margin	49.18%
Pretax Margin	52.54%
Profit Margin	52.54%
EBITDA Margin	56.61%
EBIT Margin	49.18%
FCF Margin	12.80%

Dividends & Yields

HeXun Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.22%
Shareholder Yield	-10.22%
Earnings Yield	3.53%
FCF Yield	0.86%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HeXun Biosciences has an Altman Z-Score of 30.78.

Altman Z-Score	30.78
Piotroski F-Score	n/a